STOCK TITAN

Volitionrx SEC Filings

VNRX NYSE

Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

VolitionRx’s SEC filings are packed with pages of nucleosomics data, clinical-trial updates and financing details that can overwhelm even seasoned analysts. Missing a single Form 8-K about a new licensing deal or overlooking insider buying in a Form 4 could distort your view of this diagnostics innovator. Stock Titan’s AI turns those dense disclosures into clear takeaways, so you can focus on the science and the numbers that move VNRX’s valuation.

Our platform ingests every submission to EDGAR the instant it drops and produces plain-English highlights, red-flag alerts and side-by-side comparisons. Whether you’re searching for “VolitionRx quarterly earnings report 10-Q filing” or need “VolitionRx insider trading Form 4 transactions” before market open, we have you covered. Key documents are mapped to the insights they contain:

  • 10-K / annual report — cash-burn trends, patent status, and pipeline milestones in one “VolitionRx annual report 10-K simplified” summary.
  • 10-Q / quarterly earnings — segment spending, licensing revenue and trial enrollment metrics with concise “VolitionRx earnings report filing analysis”.
  • 8-K — real-time alerts on material events; think “VolitionRx 8-K material events explained” minutes after filing.
  • Form 4 — “VolitionRx Form 4 insider transactions real-time” so you can track executive stock moves the moment they file.
  • DEF 14A proxy — drill into “VolitionRx proxy statement executive compensation” without digging through appendices.

Use Stock Titan’s AI-powered summaries, red-flag detectors and historical sidebars to understand R&D spend, dilution risk and partnership economics—“understanding VolitionRx SEC documents with AI” has never been easier. Schedule custom alerts, export tables for models and compare “VolitionRx executive stock transactions Form 4” against peer trends, all from one screen.

Filing
Rhea-AI Summary
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

New England Realty Associates Limited Partnership (ticker: NEN) filed an amended Form 4 reporting a very small disposition of partnership interests by President and Director Ronald Brown on 30-Jun-2025.

  • Units sold back to partnership: 0.3 General Partner Units (indirect) and 5.8 Class B Limited Partner Units (direct), coded “J” to indicate the transaction was executed under the partnership’s 2020 equity repurchase program.
  • Pricing: The transaction price was disclosed as $2,311.01, derived from the contemporaneous buy-back price of $77.03 per Depositary Receipt (each equal to 1/30th of a Class A Unit).
  • Post-trade ownership: Brown retains 291.4 General Partner Units indirectly (via a closely-held corporation of which he owns 75%) and 5,536.1 Class B Units directly, meaning less than 1% of his economic stake was tendered.

The filing signals routine participation in the partnership’s authorized repurchase plan rather than a market sale, and the volumes are immaterial relative to Brown’s overall holdings and to NEN’s total outstanding units.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Summary

Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.

The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.

The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.

The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.

The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Citigroup Inc. (C) filed a Form 4 indicating that non-employee director Gary M. Reiner received an equity award on 07/01/2025. The award added 538 shares of common stock to his direct holdings under the company’s Compensation Plan for Non-Employee Directors. The filing lists a reference price of $83.528 per share and shows Mr. Reiner now directly owns 46,861.4175 Citigroup shares. No sales, options, or other derivative securities were reported.

The “A” transaction code confirms the shares were granted—not purchased in the open market—making this a routine board compensation event. Given Citigroup’s roughly 2 billion shares outstanding, the incremental issuance is immaterial to the company’s capital structure and unlikely to influence market supply–demand dynamics. Nevertheless, the award incrementally aligns the director’s incentives with shareholders by modestly increasing his equity stake.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Form 144 filed for Roblox Corporation (NYSE: RBLX) discloses that insider Matthew D. Kaufman intends to sell up to 6,000 common shares on or about 3 July 2025 through Charles Schwab & Co. at an aggregate market value of $615,480. The block equals roughly 0.001 % of Roblox’s 629,990,658 shares outstanding.

The shares derive from equity compensation awards—restricted stock units that vested on 20 May 2023 (4,960 shares) and 20 Aug 2023 (1,040 shares). No cash consideration was paid when the awards vested.

Kaufman has been a frequent seller. During the past three months he executed six transactions totaling 51,021 shares for approximately $4.07 million in gross proceeds (dates: 3 Apr, 5 May, 15 May, 20 May, 5 Jun, 20 Jun 2025).

Under Rule 144, insiders must aggregate sales with other affiliates and certify that they possess no undisclosed material adverse information. The filing is LIVE, indicating an imminent transaction subject to customary Rule 144 volume and manner-of-sale limits.

While the upcoming sale is immaterial to Roblox’s float, ongoing disposals by a corporate insider can be monitored by investors as a potential sentiment signal.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

VolitionRx held its Annual Meeting on June 18, 2025, where stockholders approved several significant proposals. The most notable change was the approval of a Certificate of Second Amendment to increase authorized shares from 175 million to 325 million shares of common stock ($0.001 par value).

Key meeting outcomes include:

  • Election of eight board members, including CEO Cameron Reynolds, who received strong support with 36.1M votes
  • Ratification of Sadler, Gibb & Associates as independent auditors with overwhelming approval (51.2M votes in favor)
  • Approval of executive compensation through a non-binding advisory vote (34.4M votes in favor)
  • Strong support for the share authorization increase with 49.4M votes in favor

The meeting had 51.6 million shares represented out of 100.7 million outstanding shares. The amendment became effective upon filing with Delaware's Secretary of State on June 18, 2025, marking a significant expansion in the company's potential capital structure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Volitionrx (VNRX)?

The current stock price of Volitionrx (VNRX) is $0.646 as of July 16, 2025.

What is the market cap of Volitionrx (VNRX)?

The market cap of Volitionrx (VNRX) is approximately 73.4M.

What is the core focus of VolitionRx?

VolitionRx focuses on developing non-invasive and cost-effective blood tests, leveraging advanced epigenetic techniques to diagnose and monitor life-altering diseases, including cancers and NETosis-related conditions.

How does VolitionRx utilize nucleosomics in its diagnostic process?

The company’s platform measures circulating nucleosomes in bodily fluids, using this biomarker to detect the presence and progression of various diseases, ensuring precise and efficient diagnostic outcomes.

In what markets does VolitionRx operate?

VolitionRx operates globally with its research and development primarily based in Belgium, supported by operational hubs in the United States, London, and Singapore, addressing both human and veterinary diagnostic needs.

What distinguishes VolitionRx's diagnostic tests from traditional methods?

Their tests are designed to be simple, accessible, and as routine as common diagnostic tests, offering a non-invasive approach that reduces the need for expensive and invasive procedures, while maintaining high sensitivity and specificity.

How does VolitionRx generate revenue?

Revenue is generated through the development and commercialization of its diagnostic platforms as well as through licensing agreements and strategic partnerships with industry stakeholders in both human and veterinary diagnostic sectors.

What role do partnerships play in VolitionRx's strategy?

Strategic partnerships and licensing deals are crucial to VolitionRx’s market approach, facilitating product commercialization, enhancing clinical validation through collaborative studies, and expanding their global reach.

How does VolitionRx ensure the accuracy of its tests?

The company employs rigorous R&D and extensive clinical validation, using detailed study data from multi-center trials and independent research to ensure the reliability and accuracy of its blood-based diagnostic assays.

What are the applications of VolitionRx's technology in veterinary medicine?

VolitionRx has extended its diagnostic technologies to veterinary applications, developing blood tests that enable early cancer detection in animals, thereby improving health outcomes in companion animal care.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Stock Data

73.38M
83.73M
23.38%
20.36%
0.61%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
HENDERSON